Salubris, a pharmaceutical company, headquartered in Shenzhen, released its unaudited preliminary financial report today, which saw net profits of 1.45 billion yuan, up 3.98 percent year-on-year.
The total operating income rose by 8.3 percent to 4.151 billion yuan with a total operating profit of 1.735 billion yuan, an increase of 6.4 percent.
Its consistent investment in R&D and sales promotion had yielded a stable increase in sales volume of its core products as well as those of its new brands. The sales revenue from its pharmaceutical preparations maintained a steady growth rate, contributing considerably to last year’s earnings.
The Salubris was dedicated to doing research and producing cutting-edge medical products of proprietary intellectual property rights, providing cardiovascular, anti-infection, anti-allergy and anti-tumor medical solutions.
The total operating income rose by 8.3 percent to 4.151 billion yuan with a total operating profit of 1.735 billion yuan, an increase of 6.4 percent.
Its consistent investment in R&D and sales promotion had yielded a stable increase in sales volume of its core products as well as those of its new brands. The sales revenue from its pharmaceutical preparations maintained a steady growth rate, contributing considerably to last year’s earnings.
The Salubris was dedicated to doing research and producing cutting-edge medical products of proprietary intellectual property rights, providing cardiovascular, anti-infection, anti-allergy and anti-tumor medical solutions.
Latest comments